This company seems to have been delisted
Reason: Acquired by Immedica
Last recorded trade on: April 16, 2025
Source: https://www.immedica.com/en/press/immedica-completes-acquisition-marinus-pharmaceuticals-inc-2299708
Reason: Acquired by Immedica
Last recorded trade on: April 16, 2025
Source: https://www.immedica.com/en/press/immedica-completes-acquisition-marinus-pharmaceuticals-inc-2299708
Marinus Pharmaceuticals
MRNS
₹47.66
Share price
0.00%
Change (1 day)
-61.03%
Change (1 year)
Categories
Revenue for Marinus Pharmaceuticals (MRNS)
Revenue in 2024 (TTM): ₹2.62 Billion
According to Marinus Pharmaceuticals's latest financial reports the company's current revenue (TTM 
) is ₹2.72 Billion. In 2023 the company made a revenue of ₹2.57 Billion an increase over the revenue in the year 2022 that were of ₹2.10 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Marinus Pharmaceuticals from 2013 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 (TTM) | ₹2.62 B | 1.8% |
| 2023 | ₹2.57 B | 22.36% |
| 2022 | ₹2.10 B | 84.59% |
| 2021 | ₹1.14 B | 809.03% |
| 2020 | ₹0.12 B | |
| 2019 | N/A | |
| 2018 | N/A | |
| 2017 | N/A | |
| 2016 | N/A | |
| 2015 | N/A | |
| 2014 | N/A | |
| 2013 | N/A |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 AcelRx Pharmaceuticals
ACRX | ₹56.4 M | -97.93% | 🇺🇸 USA |
 Eagle Pharmaceuticals
EGRX | ₹22.31 B | 718.51% | 🇺🇸 USA |
 Endo International
ENDPQ | ₹174.29 B | 6,292.67% | 🇮🇪 Ireland |
 Supernus Pharmaceuticals
SUPN | ₹57.88 B | 2,022.92% | 🇺🇸 USA |